Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical donor SCT versus autologous SCT with or without decitabine maintenance in AML first remission
ChiCTR-TRC-14004196Phase 4Recruiting
- Sponsor
- Department of Hematology, The First Affiliated Hospital of Soochow University
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of decitabine in acute myeloid leukemia (AML) (2 arms), sponsored by Department of Hematology, The First Affiliated Hospital of Soochow University. Primary endpoints: Leukemia-free survival, Non-relapse mortality and 2 more. Started Jan 2014; status: recruiting.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-TRC-14004196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004196.